Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

NCT05321602 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Psychotic Disorders
Mood Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depression
Physiological Effects of Drugs
Psychotropic Drugs
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

Interventions

DRUG: LY03010 156 mg treatment group, deltoid
DRUG: LY03010 156 mg treatment group, gluteal
DRUG: LY03010 351 mg treatment group, deltoid
DRUG: LY03010 351 mg treatment group, gluteal

Sponsor

Luye Pharma Group Ltd.